

IX. APPENDIX A

Table A1
Enrollment by Study Site for Protocol 92-04-01

Site No.	Institution	Investigator	# CTCL pts./ total pts.
100	Northwestern University Medical Center	Timothy Kuzel, M.D.	9 / 15
200	Boston University Medical Center	Francine Foss, M.D.	6 / 10
300	Beth Israel Hospital, Boston	Gary Schwartz, M.D.	0 / 4
400	Loyola University	Leon Platanias, M.D.	1 / 6
500	University of Alabama	Monsoor Saleh, M.D.	12 / 18
600	University of Chicago	Mark Ratain, M.D.	1 / 2
700	University of Texas at San Antonio	C. Frederick LeMaistre, M.D./ Cesear Freytes, M.D.	4 / 15
800	University of Pennsylvania	Alain Rook, M.D.	1 / 1
900	South Texas Cancer Center	C. Frederick LeMaistre, M.D.	1 / 2

APPENDIX (continued):

TABLE A2: Investigator Sites for Protocol 93-04-10

Site	Institution	Investigator	# Randomized Pts.	# Responders (DERC)
01	University of Michigan, Ann Arbor, MI	Glen Bowen, M.D.	2 → 9 µg/kg/d 2 → 18 µg/kg/d	0 responses (0%)
02	University of Texas, M.D. Anderson Cancer Center, Houston, TX	Madeleine Duvic, M.D.	4 → 9 µg/kg/d 3 → 18 µg/kg/d	2 responses (29%); All 18 µg/kg/d
03	University of Pittsburgh Medical Center, Clinical Research Medical Center, Pittsburgh, PA	Brian Jegasothy, M.D.	2 → 9 µg/kg/d 2 → 18 µg/kg/d	3 responses (75%) 2 → 9 µg/kg/d 1 → 18 µg/kg/d
04	Boston University Medical Center, Boston, MA	Francine Foss, M.D.	1 patient at 9 µg/kg/d	1 response (100%) at 9 µg/kg/d
05	Hollings Cancer Center Medical, University of South Carolina, Charleston, SC	Arthur Frankel, M.D.	3 → 9 µg/kg/d 3 → 18 µg/kg/d	3 responses (50%) 1 → 9 µg/kg/d 2 → 18 µg/kg/d
06	University of Colorado Health Sciences Center, Denver, CO	L. Michael Glode, M.D.	1 patient at 9 µg/kg/d	0 responses (0%)
07	Yale University School of Medicine, Department of Dermatology, New Haven, CT	Peter Heald, M.D.	2 → 9 µg/kg/d 1 → 18 µg/kg/d	0 responses (0%)
08	Stanford University Medical Center, Dermatology Clinic, Stanford, CA	Youn Kim, M.D.	3 → 9 µg/kg/d 3 → 18 µg/kg/d	1 response (17%) at 18 µg/kg/d
09	Northwestern University, Chicago, IL	Timothy Kuzel, M.D.	1 → 9 µg/kg/d 1 → 18 µg/kg/d	1 response (50%) at 9 µg/kg/d
10	University of Texas Health Science Center, San Antonio, TX	C. Frederick LeMaistre, M.D.	0	
11	Duke University Medical Center, Division of Dermatology, Durham, NC	Elise Olsen, M.D.	4 → 9 µg/kg/d 4 → 18 µg/kg/d	3 responses (38%) 1 → 9 µg/kg/d 2 → 18 µg/kg/d
12	University of Alabama at Birmingham, Comprehensive Cancer Center, Birmingham, AL	Mansoor Saleh, M.D.	0	
13	Scripps Clinic, La Jolla, CA	Allan Saven, M.D.	0	
14	Roswell Park Cancer Institute, Buffalo, NY	Allan Oseroff, M.D., Ph.D.	2 → 9 µg/kg/d 1 → 18 µg/kg/d	0 responses (0%)
15	Vanderbilt University, Division of Medical Oncology, Nashville, TN	Stanford Stewart, MD	1 patient at 9 µg/kg/d	0 responses (0%)
16	Hahnemann University, Philadelphia, PA	Eric Vonderheid, M.D.	2 → 9 µg/kg/d 3 → 18 µg/kg/d	2 responses (40%) 1 → 9 µg/kg/d 1 → 18 µg/kg/d
18	Sunnybrook Health Science Centre, Toronto, Ontario, Canada	Daniel Sauder, M.D.	0	
20	University Hospitals of Cleveland, Cleveland, OH	Gary Wood, M.D.	1 → 9 µg/kg/d 3 → 18 µg/kg/d	0 responses (0%)
21	Henry Ford Hospital, Detroit, MI	David Fivenson, M.D.	1 → 9 µg/kg/d 1 → 18 µg/kg/d	0 responses (0%)
22	Indiana University Medical Center, Indianapolis, IN	Michael Gordon, M.D.	1 → 9 µg/kg/d 2 → 18 µg/kg/d	0 responses (0%)
23	Olive View- UCLA Medical Center, Sylmar, CA	Lauren Pinter-Brown, M.D.	1 → 9 µg/kg/d 2 → 18 µg/kg/d	1 response (33%) at 9 µg/kg/d
24	City of Hope National Medical Center, Duarte, CA	Arturo Molina, M.D.	1 patient at 18 µg/kg/d	0 responses (0%)
25	University of South Florida, Bay Pines, FL	Daniel Hogan, M.D.	0	
26	Washington University School of Medicine, St Louis, MO	Ann Martin, M.D.	3 → 9 µg/kg/d 3 → 18 µg/kg/d	3 responses (50%) 1 → 9 µg/kg/d 2 → 18 µg/kg/d
27	Columbia-Presbyterian Medical Center, New York, NY	Elizabeth Knobler, M.D.	1 patient at 18 µg/kg/d	1 response (100%) at 18 µg/kg/d

APPENDIX (continued):

Table A3a
Incidence (by Protocol) of Hypotension as a Component of VLS

Protocol	No. (%) of Patients with hypotension				Treated (Tox. Grade)
	Gr. 1-2	Gr. 3-4	All Grade	# D/C'd 2° ↓BP	
92-04-01 (n =73 pts)	36 pts (49 %)	4 pts (6 %)	40 pts (55 %)	0 pts (0 %)	7 pts (Gr. ½) 2 pts (Gr. ¾)
93-04-10 (n =71 pts)	5 pts (7 %)	7 pts (10 %)	12 pts (17 %)	1 pt (1 %)	0 pts (Gr. ½) 3 pts (Gr. ¾)
Combined (n= 144)	41 pts (28%)	11 pts (8 %)	52 pts (36%)	1 pt (0.7 %)	7 pts (Gr. ½) 5 pts (Gr. ¾)

Table A3b
**Patients with Hypotension Attributed to
VLS and to Hypersensitivity-Type Reaction**

Pt. No.	Course / Day	Date of ↓'ed BP	Grade	Action
Phase II (Protocol 92-04-01)				
103	C1 D1	Dec 7-8, '92	2	Tx
106	C1 D5	Dec 11, '92	2	Tx
115	C1 D2	Sep 14, '93	2	None;
	C2 D1	Oct 13, '93	2	Tx d/c
116	C1 D2	Jul 28 - Aug 5, '93	2	None
122	C1 D3	Mar 30, '94	2	Tx
127	C1 D2	May 24 - Jun 4, '94	3	Tx
128	C1 D1	Jun 20-24, '94	1	None
131	C1 D1	Jul 25 - Aug 2, '94	2	Tx d/c
136	C2 D2	Jan 31- Feb 1, '95	1	None
229	C1 D3	Jun 8 -10, '94	1	None
307	C4 D3	Jun 30 - Jul 2, '93	2	Tx
538	C2 D2	Jun 21, '94	2	None;
	C4 D2	Aug 2, '94	1	none
549	C1 D4	Aug 25 - 26, '94	2	Tx
558	C1 D1	Nov 7 -11, '94	1	None
Phase III (Protocol 93-04-10)				
502	C2 D1	Jan 2 - 6, '96	3	Withheld tx
1104	C2 D2	Jan 9 - Feb 27, '96	4	Hospitalized
1418	C1 D11	Jul 4 -19, '96	4	D/C tx
2003	C2 D2	Mar 12 -15, '96	2	Other;
	C3 D3	Apr 3, '96	1	Other
2301	C1 D4	Oct 5 - 8, '95	3	Tx; withdrew tx

APPENDIX (continued):

Table A4
Patients with Edema attributed to VLS

Pt. No.	Course / Day	Date of Edema	Grade	Action
Phase II (Protocol 92-04-01)				
102	C1 D2	Oct 20, '92	2	Tx
106	C1 D5	Dec 11 - 14, '92	1	None
116	C1 D5	Jul 31, '93	2	Tx
122	C1 D3	Mar 30, '94	2	Tx
128	C1 D1	Jun 20, '94	2	None
131	C1 D9	Aug 2 - 10, '94	1	None
205	C1 D10	Dec 23, '92	2	None
307	C4 D3 (orbit) C4D3 (perip.)	Jun 30 - Jul 5, '93 Jun 30 - Jul 13, '93	1 1	None; none
537	C1D14 (perip) C1D14 (pulm)	May 8, '94 May 8 - 19, '94	1 3	Tx Tx
549	C1 D7	Aug 28, '94	3	None
560	C1 D3	Dec 14, '94 to Jan 3, '95	1	None
902	C1D1	Nov 28, '94	2	Tx
Phase III (Protocol 93-04-10)				
202	C1 D4 (pulm)	Apr 7 - 30, '96	4	D/C study
216	C1 D3 C1 D11	Apr 27 - 28, '96 May 5 - 7, '96	2 1	None; none
217	C1 D4	Nov 12 - 20, '95	4	Tx
218	C1 D7	Jul 31 - Sep 11, '95	2	Tx
319	C1 D11 C2 D8	Jun 13 - 16, '96 Jul 8 - 10, '96	2 4	None; Tx
320	C3 D10	Apr 1 - May 14, '96	1	None
502	C1 D6	Dec 16, '95 - Jan 2, '96	2	None
718	C1 D1	Jun 24 - Jul 7, '96	4	Other
901	C1 D12	Feb 9 - 19, '96	2	Tx
1104	C2 D3	Jan 10- 14, '96	3	Tx
1120	C1 D1 C1D1 (R.arm)	De 11, '95-Fe 2, '96 De 11, '95-Ja 9, '96	3 2	None None
1418	C1 D1	Jun 24 - Jul 26, '96	3	Tx
1420	C1 D3 C2 D4 C5 D5	Feb 28 - Mar 21, '96 Apr 4 - 12, '96 Jun 28 - Jul 23, '96	3 3 1	Tx Tx None
2001 2003	C7 D7 C3D11 (pulm)	Jan 8 - 24, '96 Apr 11 - 19, '96	1 4	Other Tx, hospital
2303	CI D9 CI D13 (pulm)	De 19, '95-Ja 18, '96 De 23, '95-Ja 05, '96	2 3	Tx Tx
2720	CI D1	Jun 17 - Jul 8, '96	4	Tx

APPENDIX A(continued):

TABLE A5:SUMMARY OF CARDIAC EVENTS (PROTOCOLS 92-04-01 & 93-04-10)

Pt. No. (and dose)	Dysrhythmia (and Grade)	Cycle & Length (Treatment)	Details
Protocol 92-04-01			
205 (9 µ/kg/day)	Tachycardia (Grade 1)	C1 D3 - 6 (No therapy needed)	77 y/o; no cardiac hx, with nml EKG; cardiac episode associated with DAB ₃₈₉ IL2-induced fever and chills
	Sinus Arrhythmia (Grade 1)	C2 D2 - 12 (Withheld DAB ₃₈₉ IL2; pt was hospitalized for monitoring during doses 3-4)	PAC's and PVC's on EKG, but asymptomatic.
	Atrial Fibrillation with rapid ventricular response (Grade 3)	C2 D5 - 9 (D/C'ed DAB ₃₈₉ IL2; converted on digoxin and continued digoxin)	Dose #5 was not administered; cardiac studies (EKG and echocardiogram) were WNL.
302 (6 µ/kg/day)	Palpitations (Grade 1)	C1 D5 (No therapy needed)	67 y/o w/ hx of sick sinus synd.; no other information.
567 (31 µ/kg/day)	Tachycardia (Grade 1)	C1 D2 (Withheld and then D/C'ed DAB ₃₈₉ IL2; received 2 of 5 scheduled doses)	77 y/o w/ hx of NIDDM, aortic aneurysm, and HTN; occurred with Gr. 4 fatigue and Gr. 3 dyspnea on exertion, possibly related to tx
569 (31 µ/kg/day)	Increased pulse (Grade 1)	C1 D3 - 15 (No therapy needed; received 4/5 DAB ₃₈₉ IL2 scheduled doses)	33 y/o w/ hx of multiple therapies for HD; occurred with fatigue/general malaise x 2 weeks
718 (19 µ/kg/day)	Tachycardia (Grade2)	C1 D1 (DAB ₃₈₉ IL2 was D/C'ed C1 D2 due to hypersensitivity-type reaction)	32 y/o, s/p high-dose chemo w/ PBSC; occurred with fever and erythematous rash

TABLE A5:SUMMARY OF CARDIAC EVENTS (PROTOCOLS 92-04-01 & 93-04-10)

Pt. No. (and dose)	Dysrhythmia (and Grade)	Cycle & Length (Treatment)	Details
Protocol 92-04-01 (continued)			
739 (19 μ/kg/day)	Tachycardia (Grade 1)	C1 D3 (No therapy needed)	52 y/o, s/p mult. chemotx.; ? part of constellation of constitutional sx's
	Tachycardia (Grade 1)	C2 D?? (No therapy needed)	
748 (23 μ/kg/day)	Tachycardia (Grade 1)	C2 D2 (No therapy needed; eventually D/C'ed DAB ₃₈₉ IL2 due to constellation of constitutional sx's)	42 y/o w/ hx of PBSC tx after tx with BCNU and XRT, w/ resultant BCNU pulmonary toxicity.
901 (27 μ/kg/day)	Tachycardia (Grade 1)	C1 D21 (No therapy needed; eventually D/C'ed DAB ₃₈₉ IL2 on C 1 D34 due to pneumonia; ;pt had received all 5 doses)	24 y/o w/ hx of multiple chemotherapeutic regimens, as well as XRT and PBSC transplantation. No additional information regarding cardiac events.
Protocol 93-04-10			
120 (9 μ/kg/day)	Tachycardia (Grade 3)	C3 D1 (Withdrew DAB ₃₈₉ IL2 for D 2-5; needed O ₂ , Benadryl, and IVF's for concomitant hypotensive episode)	77 y/o w/ h/o valvular heart dz. hypothyroidism, and anemia;had subacute bacterial endocarditis dxed C3 D2 - 62; DAB ₃₈₉ IL2 was D/C'ed C3 D78 (pt also had CHF: C3 D1 - 23)
1202 (9 μ/kg/day)	Sinus tachycardia (Grade 2)	C1 D1 -8 (No cardiac therapy; pt also had concomitant pneumonia (C 1 D3 - 27)	64 y/o w/ h/o cardiac murmur; ultimately D/C'ed DAB ₃₈₉ IL2 due to pulmonary edema (during C1)
216 (9 μ/kg/day)	Tachycardia (Grade 1)	C1 D9 - 13 (No therapy needed)	36 y/o w/o cardiac hx; had concomitant conjunctivitis, itching, and otitis externa
	Palpitations (Grade 1)	C2 D1 (No therapy needed)	No other information

TABLE A5:SUMMARY OF CARDIAC EVENTS (PROTOCOLS 92-04-01 & 93-04-10)

Pt. No. (and dose)	Dysrhythmia (and Grade)	Cycle & Length (Treatment)	Details
Protocol 93-04-10 (continued)			
301 (18 µ/kg/day)	Tachycardia (Grade 4)	C1 D3 - 4 (Withheld DAB389IL2 and hospitalized pt; resolved and pt continued w/ C2)	50 y/o w/o cardiac hx; possibly related to the DAB3 89IL2
319 (18 µ/kg/day)	T-wave Inversion (Grade 3)	C2 D8 - 9 (No therapy needed; concomitant illnesses were CHF (C2 D8 - 34) and VLS (C2 D8 - 18)	76 y/o w/ h/o HTN txed w/ enalapril; concomitant illnesses were CHF (C2 D8 - 34) and VLS (C2 D8 - 18),
	Addendum: s/p MI	C2 D23	
817 (9 µ/kg/day)	Cardiac Arrhythmia (Grade 4)	C1 D4 - 5 (D/C'ed DAB389IL2 and hospitalized; treated in an emergency room; a. fib. Converted back to normal sinus rhythm on the same day)	61 y/o w/ h/o atrial fibrillation; other symptoms included were shaking chills, dizziness, and chest pain; CPK enzymes were elevated
901 (9 µ/kg/day)	Tachycardia (Grade 1)	C1 D10 (Given adenosine)	48 y/o w/o cardiac hx; occurred w/ acute hypersensitivity-type reaction
1104 (18 u/kg/day)	Arrhythmia w/ left bundle branch block and PAC's (Grade 2)	C2 D23 -213 (No therapy needed; pt also had hypotension, Grade 4. on C2 D1 - D25)	70 y/o w/ h/o HTN, angina and PAC's; DAB389IL2 was D/C'ed due to altered mental status w/ short-term memory loss from C1 D1 to C2 D51.
2002 (18 u/kg/day)	EKG (inverted T- waves) changes / Angina (Grade 2)	C1 D1 -2 (Discontinued DAB389IL2 and hospitalized)	70 y/o w/ h/o HTN and pericarditis: during cardiac eval.. was noted to have mitral and tricuspid regurgitation as well as aortic insuff. (mild)

TABLE A5:SUMMARY OF CARDIAC EVENTS (PROTOCOLS 92-04-01 & 93-04-10)

Pt. No. (and dose)	Dysrhythmia (and Grade)	Cycle & Length (Treatment)	Details
Protocol 93-04-10 (continued)			
2301 (18 μ /kg/day)	Cardiac arrest	C6 D30	71 y/o w/ h/o obesity tolerated 6 cycles of therapy with only 2 episodes of AE's - both dehydration and fever on C1D3. On C6D23, pt appeared confused and had 25-30 pounds of weight loss since the previous visit. Pt died in nursing home.
Addendum			
Protocol 93-04-10			
2601 (18 u/kg/day)	s/p MI x 2	1 st on CI D15; 2 nd on CI D31 (Death on D3 1)	68 y/o w/ h/o CAD being s/p CABG in 1985, thoracic aortic aneurysm, & angina pectoris; pt died during surgical repair of a left groin pseudoaneurysm

Protocol 94-03-11: LIST OF SERIOUS ADVERSE EVENTS

PT. NO.	GRADE	SERIOUS ADVERSE EVENT	CYCLE
254	Grade 4	Capillary fragility, increase	Cycle 1
	Grade 3	Respiratory distress	Cycle 1
351	Grade 3	Paresthesia	Cycle 7
451	Grade 4	Abdominal Pain	Cycle 6
	Grade 3	Hypertension	Cycle 6
453	Grade 4	Vascular Leak Syndrome	Cycle 1
474	Grade 3	Syncope	Cycle 3
552	Grade 4	Vascular Leak Syndrome	Cycle 1
553	Grade 4	Pericardial effusion	Cycle 3
	Grade 4	Lymphoma-like reactions	Cycle 5
573	Grade 4	Hyperglycemia	Cycle 2
	Grade 4	Cellulitis	Cycle 2
574	Grade 1	Fever	Cycle 1
851	Grade 1	Basal cell (skin) carcinoma	Cycle 2
	Grade 1	Basal cell (skin) carcinoma	Cycle 3
	Grade 3	Prostate carcinoma	Cycle 5
	Grade 1	Basal cell (skin) carcinoma	Cycle 6
	Grade 1	Basal cell (skin) carcinoma	Cycle 6
854	Grade 4	Dehydration	Cycle 1
953	Grade 3	Rash	Cycle 2
	Grade 3	Hypotension	Cycle 2
	Grade 3	Hypoalbuminemia	Cycle 2
1156	Grade 4	Urinary tract infection	Cycle 1
	Grade 4	Fever	Cycle 1
	Grade 4	Pancreatitis	Cycle 1
1274	Grade 4	Cellulitis	Cycle 3
2453	Grade 4	CNS Neoplasm (Astrocytoma)	Cycle 7
	Grade 5	Death	Cycle 7

Protocol-W-04-14: LIST OF SERIOUS ADVERSE EVENTS

PATIENT ID #	GRADE	SERIOUS ADVERSE EVENT	CYCLE
3151	4	Pneumonia, Dyspnea	9
	4	Skin Colonization	9
4199	4	Eosinophilia	1
	5	Death	1
5118	3	Urinary Tract Infection	5
	3	Herpes Zoster	5
7151	3	Celiulitis	1
9152	3	Hallucinations	1
	4	Hypoalbuminemia	2
	3	Fever	2
	3	Peripheral Edema	2
	3	Hallucinations	2
20174	3	Pleural Effusion	10
21151	4	Vascular Leak Syndrome	1
	4	Pulmonary Edema	1
	4	Erythema	1
	3	Sensis	1
	2	Dyspnea	1
27120	1	Squamous Cell Carcinoma	3

Protocol 94-03-1 1: LIST OF ADVERSE EVENTS LEADING TO DISCONTINUATION
OF STUDY DRUG

PATIENT ID #	TOXICITY GRADE	ADV. EVENT →DISCONTINUATION	CYCLE
151	2	Back pain	2
	2	Nausea	2
	3	Edema	2
	3	Asthma	2
254	4	Increased capillary fragility	1
255	4	Asthma	2
	3	Chest tightness	2
	3	Dyspnea	2
274	2	Urticaria	1
452	3	Dysphagia	1
474	3	Confusion	3
553	4	Lymphoma-like reaction	2
573	4	Hyperglycemia	2
	4	Cellulitis	2
674	4	Hypoalbuminemia	2
854	3	Dizziness	2
953	3	Hypoalbuminemia	2
1156	4	Pancreatitis	1
1274	3	Hypoalbuminemia	5
2453	4	CNS Neoplasm	7
	4	Death	7

Protocol 93-04-14: LIST OF ADVERSE EVENTS LEADING TO DISCONTINUATION
OF STUDY DRUG

PATIENT ID #	GRADE	ADV. EVENT →DISCONTINUATION	CYCLE
3120	3-4	Infusional/hypersensitivity-type.reaction (dyspnea, facial edema, pruritus. tachycardia. diaphoresis)	1
3151	3-4	Generalized pruritic rash	9
4199	1	Creatinine increase	1
9152	3	Hallucinations	2
16101	3	Rash	1
16120	2	Pneumonia	3
21151	4	Increased capillary fragility	1
	4, 4, 3	Pulmonary edema, rash, sepsis	1
21156	4	Rash	1

X. APPENDIX B: GRAPHIC CHANGE IN SYMPTOMS AND PALLIATIVE MEDICATION USE IN RESPONDING PATIENTS (PROTOCOL 93-04-10)


Complete or Clinical Complete Responders in Protocol 93-04-10

Change in PVAS score by treatment visit for all patients with CR or CCR



Change in medication usage by treatment visit for Patient 220 (CR)
Change in medication usage by treatment visit for Patient 818 (CCR)
Change in medication usage by treatment visit for Patient 502 (CCR)
Change in medication usage by treatment visit for Patient 1105 (CR)
Change in medication usage by treatment visit for Patient 1601 (CCR)
Change in medication usage by treatment visit for Patient 503 (CR)
Change in medication usage by treatment visit for Patient 302 (CCR)

Partial Responders in Protocol 93-04-10


Change in medication usage by treatment visit for Patient 218 (PR)
Change in medication usage by treatment visit for Patient 301 (PR)
Change in medication usage by treatment visit for Patient 320 (PR)
Change in medication usage by treatment visit for Patient 420 (PR)
Change in medication usage by treatment visit for Patient 518 (PR)
Change in medication usage by treatment visit for Patient 902 (PR)
Change in medication usage by treatment visit for Patient 1106 (PR)
Change in medication usage by treatment visit for Patient 1119 (PR)
Change in medication usage by treatment visit for Patient 1602 (PR)
Change in medication usage by treatment visit for Patient 2302 (PR)
Change in medication usage by treatment visit for Patient 2604 (PR)
Change in medication usage by treatment visit for Patient 2605 (PR)
Change in medication usage by treatment visit for Patient 2620 (PR)
Change in medication usage by treatment visit for Patient 2720 (PR)





PTSCALE





Patient = 818. CCR




Patient = 502 CCR




Patient = 1105, CR




Patient = 1601, CCR




Patient = 503, CR







STUDY=P410, MEDICATION USE, RESPONSE = PR


Untitled3(PT #218)





Untitled3(PT #301)






Untitled3(PT #=320)




Untitled3(PT #=420)










Untitled3(PT #=1106)




Untii 3(PT #=1119)








Untitled 3(PT #2604)



Untitled 3(PT #2605)



Untitled 3(PT #2620)



Untitled 3(PT #2720)

